Immunomedics' Trodelvy Will Be First ADC For Triple-Negative Breast Cancer

Trodelvy was granted an accelerated approval by the US FDA based on a Phase II study. It is the first commercial product for Immunomedics.

Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.

Immunomedics Inc. is preparing to launch Trodelvy (sacituzumab govitecan), the first antibody-drug conjugate for triple-negative breast cancer (TNBC) and its first commercial product, despite the challenges of launching a new drug in the current COVID-19 pandemic. The company laid out the strategy it will use to drive rapid brand awareness and adoption of Trodelvy and establish Immunomedics as a respected oncology partner during an investor call.

Trodelvy received accelerated approval from the US Food and Drug Administration on 22 April for metastatic TNBC after at least...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category